Effect of entacapone on colon motility and ion transport in a rat model of Parkinson’s disease

Figure 4 Utilizing scanning ion-selective electrode technique to observe the effect of entacapone on colon mucosa Cl^--flux in 6-OHDA rats. A: Application of entacapone (ENT) (200 μmol/L), diphenylamine-2, 2’-dicarboxylic acid (DPC) (1 mmol/L) and bumetanide (100 μmol/L), causing the typical performance of Cl^—flux in colon specimens in 6-OHDA Parkinson’s disease (PD) rats; B: Generalization of the roles of bumetanide and DPC on the Cl^--flux caused by ENT in colon specimens of 6-OHDA PD rats (n = 10); C: Application of ENT (200 μmol/L), preprocessing by bumetanide or DPC, causing the typical performance of Cl^—flux in colon specimens of 6-OHDA PD rats; D: Generalization of Cl^--flux caused by ENT after treatment by bumetanide and DPC in colonic specimens (n = 9); E: Application of ENT (200 μmol/L), and preprocessing by indomethacin (INDO) (10 μmol/L), causing the typical performance of Cl^—flux in colon specimens in 6-OHDA PD rats; F: Generalization of the roles of INDO on the Cl^--flux caused by ENT (n = 9, ^bP < 0.01 vs control).